Klaus Hahnenkamp1, Klaus Böhler, Heiner Wolters, Karsten Wiebe, Dietmar Schneider, Hartmut H-J Schmidt. 1. Department of Anesthesiology and Intensive Care Medicine, University Medicine Greifswald, German Organ Transplantation Foundation, North-East Donor Region, Berlin, Department of General and Visceral Surgery, University Hospital Münster, Department of Thoracic and Cardiovascular Surgery, University Hospital Münster, Department of Anaesthesiology and Intensive Care, University Hospital Leipzig, Department of Transplant Medicine, University Hospital Münster.
Abstract
BACKGROUND: The ascertainment of brain death (the irreversible, total loss of brain function) gives the physician the opportunity to limit or stop further treatment. Alternatively, if the brain-dead individual is an organ donor, the mode of treatment can be changed from patient-centered to donationcentered. Consensus-derived recommendations for the organ-protective treatment of brain-dead organ donors are not yet available in Germany. METHODS: This review is based on pertinent publications retrieved by a selective search in PubMed, and on the authors' clinical experience. RESULTS: Brain death causes major pathophysiological changes, including an increase in catecholamine levels and a sudden drop in the concentration of multiple hormones, among them antidiuretic hormone, cortisol, insulin, and triand tetraiodothyronine. These changes affect the function of all organ systems, as well as the hemodynamic state and the regulation of body temperature. The use of standardized donor management protocols might well increase the rate of transplanted organs per donor and improve the quality of the transplanted organs. In addition, the administration of methylprednisolone, desmopressin, and vasopressin could be a useful supplement to treatment in some cases. Randomized controlled trials have not yet demonstrated either improved organ function or prolonged survival of the transplant recipients. CONCLUSION: The evidence base for organ-protective intensive care is weak; most of the available evidence is on the level of expert opinion. There is good reason to believe, however, that the continuation of intensive care, in the sense of early donor management, can make organ transplantation more successful both by increasing the number of transplantable organs and by improving organ quality.
BACKGROUND: The ascertainment of brain death (the irreversible, total loss of brain function) gives the physician the opportunity to limit or stop further treatment. Alternatively, if the brain-dead individual is an organ donor, the mode of treatment can be changed from patient-centered to donationcentered. Consensus-derived recommendations for the organ-protective treatment of brain-dead organ donors are not yet available in Germany. METHODS: This review is based on pertinent publications retrieved by a selective search in PubMed, and on the authors' clinical experience. RESULTS:Brain death causes major pathophysiological changes, including an increase in catecholamine levels and a sudden drop in the concentration of multiple hormones, among them antidiuretic hormone, cortisol, insulin, and triand tetraiodothyronine. These changes affect the function of all organ systems, as well as the hemodynamic state and the regulation of body temperature. The use of standardized donor management protocols might well increase the rate of transplanted organs per donor and improve the quality of the transplanted organs. In addition, the administration of methylprednisolone, desmopressin, and vasopressin could be a useful supplement to treatment in some cases. Randomized controlled trials have not yet demonstrated either improved organ function or prolonged survival of the transplant recipients. CONCLUSION: The evidence base for organ-protective intensive care is weak; most of the available evidence is on the level of expert opinion. There is good reason to believe, however, that the continuation of intensive care, in the sense of early donor management, can make organ transplantation more successful both by increasing the number of transplantable organs and by improving organ quality.
Authors: Peter S Macdonald; Anders Aneman; Deepak Bhonagiri; Daryl Jones; Gerry O'Callaghan; William Silvester; Alasdair Watson; Geoffrey Dobb Journal: Crit Care Med Date: 2012-05 Impact factor: 7.598
Authors: M S Patel; C U Niemann; M B Sally; S De La Cruz; J Zatarain; T Ewing; M Crutchfield; C K Enestvedt; D J Malinoski Journal: Am J Transplant Date: 2015-04-22 Impact factor: 8.086
Authors: David S Plurad; Scott Bricker; Ann Falor; Angela Neville; Frederic Bongard; Brant Putnam Journal: J Trauma Acute Care Surg Date: 2012-09 Impact factor: 3.313
Authors: S Weiss; K Kotsch; M Francuski; A Reutzel-Selke; L Mantouvalou; R Klemz; O Kuecuek; S Jonas; C Wesslau; F Ulrich; A Pascher; H-D Volk; S G Tullius; P Neuhaus; J Pratschke Journal: Am J Transplant Date: 2007-04-08 Impact factor: 8.086
Authors: Darren J Malinoski; Madhukar S Patel; Michael C Daly; Chrystal Oley-Graybill; Ali Salim Journal: Crit Care Med Date: 2012-10 Impact factor: 7.598
Authors: Madhukar S Patel; John Zatarain; Salvador De La Cruz; Mitchell B Sally; Tyler Ewing; Megan Crutchfield; C Kristian Enestvedt; Darren J Malinoski Journal: JAMA Surg Date: 2014-09 Impact factor: 14.766
Authors: Peter Schnuelle; Uwe Gottmann; Simone Hoeger; Detlef Boesebeck; Werner Lauchart; Christel Weiss; Michael Fischereder; Karl-Walter Jauch; Uwe Heemann; Martin Zeier; Christian Hugo; Przemyslaw Pisarski; Bernhard K Krämer; Kai Lopau; Axel Rahmel; Urs Benck; Rainer Birck; Benito Antonio Yard Journal: JAMA Date: 2009-09-09 Impact factor: 56.272
Authors: Geert Meyfroidt; Jan Gunst; Ignacio Martin-Loeches; Martin Smith; Chiara Robba; Fabio Silvio Taccone; Giuseppe Citerio Journal: Intensive Care Med Date: 2019-02-11 Impact factor: 17.440